The human papillomavirus E7 oncoprotein

Virology

Volumn 384, Issue 2, 2009, Pages 335-344

  McLaughlin Drubin, Margaret E ^a   Münger, Karl ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cell death; Cellular metabolism; Cellular transformation; Centrosome duplication; E7 oncoprotein; Genomic instability; Human papillomavirus; p53; Retinoblastoma tumor suppressor; Ubiquitin ligase

Indexed keywords

CYTOKINE; PROTEIN E7; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN;

CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL METABOLISM; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CYTOSTASIS; EPIGENETICS; EPITHELIUM; GENOMIC INSTABILITY; HUMAN; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VIRUS CELL TRANSFORMATION; VIRUS REPLICATION; WART VIRUS;

CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, VIRAL; CHROMOSOMAL INSTABILITY; CYTOKINES; E2F TRANSCRIPTION FACTORS; EPIGENESIS, GENETIC; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

ADENOVIRIDAE; HUMAN PAPILLOMAVIRUS;

EID: 59549098296     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.10.006     Document Type: Short Survey

References (211)

1. Aisenberg A.C. Studies on normal and neoplastic mitochondria. I. Respiration Cancer Res. 21 (1961) 295-303
2. Alani R.M., Hasskarl J., and Munger K. Alterations in cyclin-dependent kinase 2 function during differentiation of primary human keratinocytes. Mol. Carcinog. 23 4 (1998) 226-233
3. Angeline M., Merle E., and Moroianu J. The E7 oncoprotein of high-risk human papillomavirus type 16 enters the nucleus via a nonclassical Ran-dependent pathway. Virology 317 1 (2003) 13-23
4. Arbeit J.M., Howley P.M., and Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 93 7 (1996) 2930-2935
5. Armstrong D.J., and Roman A. The anomalous electrophoretic behavior of the human papillomavirus type-16 E7-protein is due to the high content of acidic amino acid residues. Biochem. Biophys. Res. Commun. 192 3 (1993) 1380-1387
6. Assoian R.K. Anchorage-dependent cell cycle progression. J. Cell Biol. 136 1 (1997) 1-4
7. Attwooll C., Oddi S., Cartwright P., Prosperini E., Agger K., Steensgaard P., Wagener C., Sardet C., Moroni M.C., and Helin K. A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner. J. Biol. Chem. 280 2 (2005) 1199-1208
8. Avvakumov N., Torchia J., and Mymryk J.S. Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene 22 25 (2003) 3833-3841
9. Baldwin A., Pirisi L., and Creek K.E. NFI-Ski interactions mediate transforming growth factor beta modulation of human papillomavirus type 16 early gene expression. J. Virol. 78 8 (2004) 3953-3964
10. Baldwin A., Huh K.W., and Munger K. Human papillomavirus E7 oncoprotein dysregulates steroid receptor coactivator 1 localization and function. J. Virol. 80 13 (2006) 6669-6677
11. Baldwin A., Li W., Grace M., Pearlberg J., Harlow E., Münger K., and Grueneberg D.A. Kinase Requirements in Human Cells: II. Genetic Interaction Screens Identify Alterations in Kinase Requirements Following HPV16 E7 Expression in Cancer Cells. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 16478-16483
12. Balsitis S.J., Sage J., Duensing S., Munger K., Jacks T., and Lambert P.F. Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol. Cell. Biol. 23 24 (2003) 9094-9103
13. Barbosa M.S., Lowy D.R., and Schiller J.T. Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J. Virol. 63 3 (1989) 1404-1407
14. Barbosa M.S., Edmonds C., Fisher C., Schiller J.T., Lowy D.R., and Vousden K.H. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J. 9 1 (1990) 153-160
15. Barbosa M.S., Vass W.C., Lowy D.R., and Schiller J.T. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J. Virol. 65 1 (1991) 292-298
16. Barnard P., and McMillan N.A. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 259 2 (1999) 305-313
17. Barnard P., Payne E., and McMillan N.A. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology 277 2 (2000) 411-419
18. Basile J.R., Zacny V., and Munger K. The cytokines tumor necrosis factor-alpha (TNF-alpha) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J. Biol. Chem. 276 25 (2001) 22522-22528
19. Basile J.R., Eichten A., Zacny V., and Munger K. NF-kappaB-mediated induction of p21(Cip1/Waf1) by tumor necrosis factor alpha induces growth arrest and cytoprotection in normal human keratinocytes. Mol. Cancer Res. 1 4 (2003) 262-270
20. Bates S., Phillips A.C., Clark P.A., Stott F., Peters G., Ludwig R.L., and Vousden K.H. p14ARF links the tumour suppressors RB and p53. Nature 395 6698 (1998) 124-125
21. Bedell M.A., Jones K.H., Grossman S.R., and Laimins L.A. Identification of human papillomavirus type 18 transforming genes in immortalized and primary cells. J. Virol. 63 3 (1989) 1247-1255
22. Bernat A., Avvakumov N., Mymryk J.S., and Banks L. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 22 39 (2003) 7871-7881
23. Bettencourt-Dias M., and Glover D.M. Centrosome biogenesis and function: centrosomics brings new understanding. Nat. Rev. Mol. Cell Biol. 8 6 (2007) 451-463
24. Bibbo M., Dytch H.E., Alenghat E., Bartels P.H., and Wied G.L. DNA ploidy profiles as prognostic indicators in CIN lesions. Am. J. Clin. Pathol. 92 3 (1989) 261-265
25. Boyer S.N., Wazer D.E., and Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56 20 (1996) 4620-4624
26. Brehm A., Nielsen S.J., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., and Kouzarides T. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 18 9 (1999) 2449-2458
27. Bulten J., Poddighe P.J., Robben J.C.M., Gemmink J.H., de Wilde P.C.M., and Hanselaar A.G.J.M. Interphase cytogenetic analysis of cervical intraepithelial neoplasia. Am. J. Pathol. 152 (1998) 495-503
28. Chen W., Li F., Mead L., White H., Walker J., Ingram D.A., and Roman A. Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology 367 1 (2007) 168-174
29. Cheng S., Schmidt-Grimminger D.C., Murant T., Broker T.R., and Chow L.T. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9 19 (1995) 2335-2349
30. Ciccolini F., Di Pasquale G., Carlotti F., Crawford L., and Tommasino M. Functional studies of E7 proteins from different HPV types. Oncogene 9 9 (1994) 2633-2638
31. Clemens K.E., Brent R., Gyuris J., and Munger K. Dimerization of the human papillomavirus E7 oncoprotein in vivo. Virology 214 1 (1995) 289-293
32. Cole S.T., and Danos O. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J. Mol. Biol. 193 4 (1987) 599-608
33. Collins A.S., Nakahara T., Do A., and Lambert P.F. Interactions with pocket proteins contribute to the role of human papillomavirus type 16 E7 in the papillomavirus life cycle. J. Virol. 79 23 (2005) 14769-14780
34. Cottage A., Dowen S., Roberts I., Pett M., Coleman N., and Stanley M. Early genetic events in HPV immortalised keratinocytes. Genes Chromosomes Cancer 30 1 (2001) 72-79
35. Creek K.E., Geslani G., Batova A., and Pirisi L. Progressive loss of sensitivity to growth control by retinoic acid and transforming growth factor-beta at late stages of human papillomavirus type 16-initiated transformation of human keratinocytes. Adv. Exp. Med. Biol. 375 (1995) 117-135
36. Crum C.P., Ikenberg H., Richart R.M., and Gissman L. Human papillomavirus type 16 and early cervical neoplasia. N. Engl. J. Med. 310 14 (1984) 880-883
37. Datto M.B., Li Y., Panus J.F., Howe D.J., Xiong Y., and Wang X.F. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5545-5549
38. De Geest K., Bergman C.A., Turyk M.E., Frank B.S., and Wilbanks G.D. Differential response of cervical intraepithelial and cervical carcinoma cell lines to transforming growth factor-beta 1. Gynecol. Oncol. 55 3 Pt 1 (1994) 376-385
39. DeFilippis R.A., Goodwin E.C., Wu L., and DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J. Virol. 77 2 (2003) 1551-1563
40. DeMasi J., Huh K.W., Nakatani Y., Munger K., and Howley P.M. Bovine papillomavirus E7 transformation function correlates with cellular p600 protein binding. Proc. Natl. Acad. Sci. U. S. A. 102 32 (2005) 11486-11491
41. DeMasi J., Chao M.C., Kumar A.S., and Howley P.M. Bovine papillomavirus E7 oncoprotein inhibits anoikis. J. Virol. 81 17 (2007) 9419-9425
42. Demers G.W., Foster S.A., Halbert C.L., and Galloway D.A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. U. S. A. 91 10 (1994) 4382-4386
43. Di Cunto F., Topley G., Calautti E., Hsiao J., Ong L., Seth P.K., and Dotto G.P. Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science 280 5366 (1998) 1069-1072
44. DiPaolo J.A., Woodworth C.D., Popescu N.C., Notario V., and Doniger J. Induction of human cervical squamous cell carcinoma by sequential transfection with human papillomavirus 16 DNA and viral Harvey ras. Oncogene 4 4 (1989) 395-399
45. Duensing S., and Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 62 23 (2002) 7075-7082
46. Duensing S., and Munger K. Human papillomavirus type 16 E7 oncoprotein can induce abnormal centrosome duplication through a mechanism independent of inactivation of retinoblastoma protein family members. J. Virol. 77 22 (2003) 12331-12335
47. Duensing S., Lee L.Y., Duensing A., Basile J., Piboonniyom S., Gonzalez S., Crum C.P., and Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc. Natl. Acad. Sci. U. S. A. 97 18 (2000) 10002-10007
48. Duensing S., Duensing A., Crum C.P., and Munger K. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res. 61 6 (2001) 2356-2360
49. Duensing S., Duensing A., Flores E.R., Do A., Lambert P.F., and Munger K. Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. J. Virol. 75 16 (2001) 7712-7716
50. Duensing S., Duensing A., Lee D.C., Edwards K.M., Piboonniyom S.O., Manuel E., Skaltsounis L., Meijer L., and Munger K. Cyclin-dependent kinase inhibitor indirubin-3′-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 23 50 (2004) 8206-8215
51. Duensing A., Liu Y., Tseng M., Malumbres M., Barbacid M., and Duensing S. Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene 25 20 (2006) 2943-2949
52. Duensing A., Liu Y., Perdreau S.A., Kleylein-Sohn J., Nigg E.A., and Duensing S. Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates. Oncogene 26 43 (2007) 6280-6288
53. Duensing A., Chin A., Wang L., Kuan S.F., and Duensing S. Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms. Virology 372 1 (2008) 157-164
54. Durst M., Gallahan D., Jay G., and Rhim J.S. Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papillomavirus type 16 and an activated ras oncogene. Virology 173 2 (1989) 767-771
55. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12 15 (1998) 2245-2262
56. Dyson N., Guida P., Munger K., and Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66 12 (1992) 6893-6902
57. Edmonds C., and Vousden K.H. A point mutational analysis of human papillomavirus type 16 E7 protein. J. Virol. 63 6 (1989) 2650-2656
58. Eichten A., Westfall M., Pietenpol J.A., and Münger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. Virology 295 (2002) 74-95
59. Eichten A., Rud D.S., Grace M., Piboonniyom S.O., Zacny V., and Munger K. Molecular pathways executing the "trophic sentinel" response in HPV-16 E7-expressing normal human diploid fibroblasts upon growth factor deprivation. Virology 319 1 (2004) 81-93
60. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 4 (1993) 817-825
61. Elbendary A., Berchuck A., Davis P., Havrilesky L., Bast Jr. R.C., Iglehart J.D., and Marks J.R. Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ. 5 (1994) 1301-1307
62. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., and Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69 1 (1992) 119-128
63. Fang F., Orend G., Watanabe N., Hunter T., and Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 271 5248 (1996) 499-502
64. Figge J., Webster T., Smith T.F., and Paucha E. Prediction of similar transforming regions in simian virus 40 large T, adenovirus E1A, and myc oncoproteins. J. Virol. 62 5 (1988) 1814-1818
65. Firpo E.J., Koff A., Solomon M.J., and Roberts J.M. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol. Cell. Biol. 14 7 (1994) 4889-4901
66. Firzlaff J.M., Galloway D.A., Eisenman R.N., and Luscher B. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol. 1 1 (1989) 44-53
67. Flores E.R., Allen-Hoffmann B.L., Lee D., and Lambert P.F. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J. Virol. 74 14 (2000) 6622-6631
68. Frisch S.M., and Screaton R.A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13 5 (2001) 555-562
69. Frolov M.V., and Dyson N.J. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J. Cell. Sci. 117 Pt 11 (2004) 2173-2181
70. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., and Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11 16 (1997) 2090-2100
71. Gage J.R., Meyers C., and Wettstein F.O. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J. Virol. 64 2 (1990) 723-730
72. Gil P., Dewey E., Friml J., Zhao Y., Snowden K.C., Putterill J., Palme K., Estelle M., and Chory J. BIG: a calossin-like protein required for polar auxin transport in Arabidopsis. Genes Dev. 15 15 (2001) 1985-1997
73. Greenfield I., Nickerson J., Penman S., and Stanley M. Human papillomavirus 16 E7 protein is associated with the nuclear matrix. Proc. Natl. Acad. Sci. U. S. A. 88 24 (1991) 11217-11221
74. Grueneberg D.A., Degot S., Pearlberg J., Li W., Davies J.E., Baldwin A., Endege W., Doench J., Sawyer J., Hu Y., Boyce F., Xian J., Münger K., and Harlow E. Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 16472-16477
75. Guarguaglini G., Duncan P.I., Stierhof Y.D., Holmstrom T., Duensing S., and Nigg E.A. The forkhead-associated domain protein Cep170 interacts with Polo-like kinase 1 and serves as a marker for mature centrioles. Mol. Biol. Cell 16 3 (2005) 1095-1107
76. Gulliver G.A., Herber R.L., Liem A., and Lambert P.F. Both conserved region 1 (CR1) and CR2 of the human papillomavirus type 16 E7 oncogene are required for induction of epidermal hyperplasia and tumor formation in transgenic mice. J. Virol. 71 8 (1997) 5905-5914
77. Halbert C.L., Demers G.W., and Galloway D.A. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol. 66 (1992) 2125-2134
78. Hannon G.J., and Beach D. p15(INK4B) is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371 (1994) 257-261
79. Hashida T., and Yasumoto S. Induction of chromosome abnormalities in mouse and human epidermal keratinocytes by the human papillomavirus type 16 E7 oncogene. J. Gen. Virol. 72 Pt 7 (1991) 1569-1577
80. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., and Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8 12 (1989) 3905-3910
81. He W., Staples D., Smith C., and Fisher C. Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J. Virol. 77 19 (2003) 10566-10574
82. Heck D.V., Yee C.L., Howley P.M., and Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. U. S. A. 89 10 (1992) 4442-4446
83. Helt A.M., and Galloway D.A. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 e7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J. Virol. 75 15 (2001) 6737-6747
84. Helt A.M., Funk J.O., and Galloway D.A. Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J. Virol. 76 20 (2002) 10559-10568
85. Hengstermann A., Linares L.K., Ciechanover A., Whitaker N.J., and Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc. Natl. Acad. Sci. U. S. A. 98 3 (2001) 1218-1223
86. Heselmeyer K., Schrock E., du Manoir S., Blegen H., Shah K., Steinbeck R., Auer G., and Ried T. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc. Natl. Acad. Sci. U. S. A. 93 1 (1996) 479-484
87. Heselmeyer K., Macville M., Schrock E., Blegen H., Hellstrom A.C., Shah K., Auer G., and Ried T. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer 19 (1997) 233-240
88. Hickman E.S., Picksley S.M., and Vousden K.H. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 9 8 (1994) 2177-2181
89. Huang S.M., and McCance D.J. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J. Virol. 76 17 (2002) 8710-8721
90. Huang P.S., Patrick D.R., Edwards G., Goodhart P.J., Huber H.E., Miles L., Garsky V.M., Oliff A., and Heimbrook D.C. Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol. Cell. Biol. 13 2 (1993) 953-960
91. Hudson J.B., Bedell M.A., McCance D.J., and Laiminis L.A. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J. Virol. 64 2 (1990) 519-526
92. Huh K.W., DeMasi J., Ogawa H., Nakatani Y., Howley P.M., and Munger K. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc. Natl. Acad. Sci. U. S. A. 102 32 (2005) 11492-11497
93. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., Harper J.W., and Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 81 18 (2007) 9737-9747
94. Hurlin P.J., Kaur P., Smith P.P., Perez-Reyes N., Blanton R.A., and McDougall J.K. Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype. Proc. Natl. Acad. Sci. U. S. A. 88 2 (1991) 570-574
95. Hwang S.G., Lee D., Kim J., Seo T., and Choe J. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J. Biol. Chem. 277 4 (2002) 2923-2930
96. Jewers R.J., Hildebrandt P., Ludlow J.W., Kell B., and McCance D.J. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J. Virol. 66 3 (1992) 1329-1335
97. Jian Y., Schmidt-Grimminger D.C., Chien W.M., Wu X., Broker T.R., and Chow L.T. Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes. Oncogene 17 16 (1998) 2027-2038
98. Jones D.L., Alani R.M., and Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 11 16 (1997) 2101-2111
99. Jones D.L., Thompson D.A., and Munger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 239 1 (1997) 97-107
100. Jones D.L., Thompson D.A., Suh-Burgmann E., Grace M., and Munger K. Expression of the HPV E7 oncoprotein mimics but does not evoke a p53-dependent cellular DNA damage response pathway. Virology 258 2 (1999) 406-414
101. Kadaja M., Sumerina A., Verst T., Ojarand M., Ustav E., and Ustav M. Genomic instability of the host cell induced by the human papillomavirus replication machinery. EMBO J. 26 8 (2007) 2180-2191
102. Kamio M., Yoshida T., Ogata H., Douchi T., Nagata Y., Inoue M., Hasegawa M., Yonemitsu Y., and Yoshimura A. SOCS1 [corrected] inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein. Oncogene 23 17 (2004) 3107-3115
103. Kanda T., Furuno A., and Yoshiike K. Human papillomavirus type 16 open reading frame E7 encodes a transforming gene for rat 3Y1 cells. J. Virol. 62 2 (1988) 610-613
104. Katich S.C., Zerfass-Thome K., and Hoffmann I. Regulation of the Cdc25A gene by the human papillomavirus Type 16 E7 oncogene. Oncogene 20 5 (2001) 543-550
105. Kennedy R.D., and D'Andrea A.D. The Fanconi anemia/BRCA pathway: new faces in the crowd. Genes Dev. 19 24 (2005) 2925-2940
106. Kessis T.D., Connolly D.C., Hedrick L., and Cho K.R. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene 13 2 (1996) 427-431
107. Knapp, A.A., McManus, P.M., Bockstall, K., and Moroianu, J., in press. Identification of the nuclear localization and export signals of high risk HPV16 E7 oncoprotein. Virology.
108. Kutler D.I., Wreesmann V.B., Goberdhan A., Ben-Porat L., Satagopan J., Ngai I., Huvos A.G., Giampietro P., Levran O., Pujara K., Diotti R., Carlson D., Huryn L.A., Auerbach A.D., and Singh B. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J. Natl. Cancer Inst. 95 22 (2003) 1718-1721
109. Lee C., and Laimins L.A. The differentiation-dependent life cycle of human papillomaviruses in keratinocytes. In: Garcea R.L., and DiMaio D. (Eds). The Papillomaviruses (2007), Springer, New York 45-68
110. Liu X., Clements A., Zhao K., and Marmorstein R. Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. 281 1 (2006) 578-586
111. Longworth M.S., and Laimins L.A. The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J. Virol. 78 7 (2004) 3533-3541
112. Longworth M.S., Wilson R., and Laimins L.A. HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs. EMBO J. 24 10 (2005) 1821-1830
113. Lyons T.E., Salih M., and Tuana B.S. Activating E2Fs mediate transcriptional regulation of human E2F6 repressor. Am. J. Physiol., Cell Physiol. 290 1 (2006) C189-C199
114. Mannhardt B., Weinzimer S.A., Wagner M., Fiedler M., Cohen P., Jansen-Durr P., and Zwerschke W. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3 [In Process Citation]. Mol. Cell. Biol. 20 17 (2000) 6483-6495
115. Mannik A., Runkorg K., Jaanson N., Ustav M., and Ustav E. Induction of the bovine papillomavirus origin "onion skin"-type DNA replication at high E1 protein concentrations in vivo. J. Virol. 76 11 (2002) 5835-5845
116. Massimi P., and Banks L. Differential phosphorylation of the HPV-16 E7 oncoprotein during the cell cycle. Virology 276 2 (2000) 388-394
117. Matlashewski G., Schneider J., Banks L., Jones N., Murray A., and Crawford L. Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J. 6 6 (1987) 1741-1746
118. Mazurek S., Zwerschke W., Jansen-Durr P., and Eigenbrodt E. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem. J. 356 Pt 1 (2001) 247-256
119. McCance D.J., Kopan R., Fuchs E., and Laimins L.A. Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc. Natl. Acad. Sci. U. S. A. 85 19 (1988) 7169-7173
120. McIntyre M.C., Frattini M.G., Grossman S.R., and Laimins L.A. Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J. Virol. 67 (1993) 3142-3150
121. McLaughlin-Drubin M.E., Bromberg-White J.L., and Meyers C. The role of the human papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. Virology 338 1 (2005) 61-68
122. McLaughlin-Drubin M.E., Huh K.W., and Munger K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J. Virol. 82 17 (2008) 8695-8705
123. Missero C., Di Cunto F., Kiyokawa H., Koff A., and Dotto G.P. The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev. 10 23 (1996) 3065-3075
124. Mitelman, F., Johansson, B., and Mertens, F., 2007. "Mitelman database of chromosome aberrations in cancer (2007), http://cgap.nci.nih.gov/Chromosomes/Mitelman."
125. Mogk A., Schmidt R., and Bukau B. The N-end rule pathway for regulated proteolysis: prokaryotic and eukaryotic strategies. Trends Cell Biol. 17 4 (2007) 165-172
126. Munger K., Phelps W.C., Bubb V., Howley P.M., and Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63 10 (1989) 4417-4421
127. Munger K., Werness B.A., Dyson N., Phelps W.C., Harlow E., and Howley P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8 13 (1989) 4099-4105
128. Münger K., Yee C.L., Phelps W.C., Pietenpol J.A., Moses H.L., and Howley P.M. Biochemical and biological differences between E7 oncoproteins of the high- and low risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 65 (1991) 3943-3948
129. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., and Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78 21 (2004) 11451-11460
130. Nguyen C.L., Eichwald C., Nibert M.L., and Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the centrosomal component gamma-tubulin. J. Virol. 81 24 (2007) 13533-13543
131. Nguyen C.L., McLaughlin-Drubin M.E., and Münger K. Delocalization of the microtubule motor dynein from mitotic spindles by the human papillomavirus E7 oncoprotein is not sufficient for induction of multipolar mitoses. Cancer Res. 68 22 (2008) 8715-8722
132. Nguyen C.L., and Munger K. Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes. Virology 380 1 (2008) 21-25
133. Noya F., Chien W.M., Broker T.R., and Chow L.T. p21cip1 Degradation in differentiated keratinocytes is abrogated by costabilization with cyclin E induced by human papillomavirus E7. J. Virol. 75 13 (2001) 6121-6134
134. Ogawa H., Ishiguro K., Gaubatz S., Livingston D.M., and Nakatani Y. A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G0 cells. Science 296 5570 (2002) 1132-1136
135. Oh K.J., Kalinina A., Wang J., Nakayama K., Nakayama K.I., and Bagchi S. The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. J. Virol. 78 10 (2004) 5338-5346
136. Oh S.T., Longworth M.S., and Laimins L.A. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. J. Virol. 78 5 (2004) 2620-2626
137. Ohlenschlager O., Seiboth T., Zengerling H., Briese L., Marchanka A., Ramachandran R., Baum M., Korbas M., Meyer-Klaucke W., Durst M., and Gorlach M. Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7. Oncogene 25 44 (2006) 5953-5959
138. Park J.S., Kim E.J., Kwon H.J., Hwang E.S., Namkoong S.E., and Um S.J. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem. 275 10 (2000) 6764-6769
139. Patrick D.R., Oliff A., and Heimbrook D.C. Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein. J. Biol. Chem. 269 9 (1994) 6842-6850
140. Pedersen S.N. Enzymatic studies of glycogen metabolism in nonmalignant and malignant biopsies from the human uterine cervix. Acta Obstet. Gynecol. Scand. 54 5 (1975) 443-448
141. Pei X.F., Meck J.M., Greenhalgh D., and Schlegel R. Cotransfection of HPV-18 and v-fos DNA induces tumorigenicity of primary human keratinocytes. Virology 196 2 (1993) 855-860
142. Perea S.E., Massimi P., and Banks L. Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. Int. J. Mol. Med. 5 6 (2000) 661-666
143. Pett M.R., Alazawi W.O., Roberts I., Dowen S., Smith D.I., Stanley M.A., and Coleman N. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res. 64 4 (2004) 1359-1368
144. Phelps W.C., Yee C.L., Munger K., and Howley P.M. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53 4 (1988) 539-547
145. Phelps W.C., Münger K., Yee C.L., Barnes J.A., and Howley P.M. Structure-function analysis of the human papillomavirus E7 oncoprotein. J. Virol. 66 (1992) 2418-2427
146. Pietenpol J.A., Stein R.W., Moran E., Yaciuk P., Schlegel R., Lyons R.M., Pittelkow M.R., Munger K., Howley P.M., and Moses H.L. TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 61 5 (1990) 777-785
147. Polyak K. Negative regulation of cell growth by TGF beta. Biochim. Biophys. Acta 1242 3 (1996) 185-199
148. Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M., and Koff A. p27(kip1), a cyclin-cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8 (1994) 9-22
149. Quintyne N.J., Reing J.E., Hoffelder D.R., Gollin S.M., and Saunders W.S. Spindle multipolarity is prevented by centrosomal clustering. Science 307 5706 (2005) 127-129
150. Reinstein E., Scheffner M., Oren M., Ciechanover A., and Schwartz A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 19 51 (2000) 5944-5950
151. Reshkin S.J., Bellizzi A., Caldeira S., Albarani V., Malanchi I., Poignee M., Alunni-Fabbroni M., Casavola V., and Tommasino M. Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J. 14 (2000) 2185-2197
152. Ressler S., Scheiden R., Dreier K., Laich A., Muller-Holzner E., Pircher H., Morandell D., Stein I., Viertler H.P., Santer F.R., Widschwendter A., Even J., Jansen-Durr P., Capesius C., and Zwerschke W. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin. Cancer Res. 13 23 (2007) 7067-7072
153. Richards S., Hillman T., and Stern M. Mutations in the Drosophila pushover gene confer increased neuronal excitability and spontaneous synaptic vesicle fusion. Genetics 142 4 (1996) 1215-1223
154. Rihet S., Lorenzato M., and Clavel C. Oncogenic human papillomaviruses and ploidy in cervical lesions. J. Clin. Pathol. 49 11 (1996) 892-896
155. Riley R.R., Duensing S., Brake T., Munger K., Lambert P.F., and Arbeit J.M. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 63 16 (2003) 4862-4871
156. Rosl F., Achtstatter T., Bauknecht T., Hutter K.J., Futterman G., and zur Hausen H. Extinction of the HPV18 upstream regulatory region in cervical carcinoma cells after fusion with non-tumorigenic human keratinocytes under non-selective conditions. EMBO J. 10 6 (1991) 1337-1345
157. Ruesch M.N., and Laimins L.A. Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. J. Virol. 71 7 (1997) 5570-5578
158. Sang B.C., and Barbosa M.S. Single amino acid substitutions in "low-risk" human papillomavirus (HPV) type 6 E7 protein enhance features characteristic of the "high-risk" HPV E7 oncoproteins. Proc. Natl. Acad. Sci. U. S. A. 89 17 (1992) 8063-8067
159. Santer F.R., Moser B., Spoden G.A., Jansen-Durr P., and Zwerschke W. Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor-binding protein-3 by enhancing its ubiquitin/proteasome-dependent degradation. Carcinogenesis 28 12 (2007) 2511-2520
160. Sato H., Watanabe S., Furuno A., and Yoshiike K. Human papillomavirus type 16 E7 protein expressed in Escherichia coli and monkey COS-1 cells: immunofluorescence detection of the nuclear E7 protein. Virology 170 1 (1989) 311-315
161. Schaeffer A.J., Nguyen M., Liem A., Lee D., Montagna C., Lambert P.F., Ried T., and Difilippantonio M.J. E6 and E7 oncoproteins induce distinct patterns of chromosomal aneuploidy in skin tumors from transgenic mice. Cancer Res. 64 2 (2004) 538-546
162. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 9590 (2007) 890-907
163. Schlegel R., Phelps W.C., Zhang Y.L., and Barbosa M. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J. 7 10 (1988) 3181-3187
164. Seavey S.E., Holubar M., Saucedo L.J., and Perry M.E. The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF). J. Virol. 73 9 (1999) 7590-7598
165. Sekelsky J.J., McKim K.S., Messina L., French R.L., Hurley W.D., Arbel T., Chin G.M., Deneen B., Force S.J., Hari K.L., Jang J.K., Laurencon A.C., Madden L.D., Matthies H.J., Milliken D.B., Page S.L., Ring A.D., Wayson S.M., Zimmerman C.C., and Hawley R.S. Identification of novel Drosophila meiotic genes recovered in a P-element screen. Genetics 152 2 (1999) 529-542
166. Shim S.Y., Wang J., Asada N., Neumayer G., Tran H.C., Ishiguro K., Sanada K., Nakatani Y., and Nguyen M.D. Protein 600 is a microtubule/endoplasmic reticulum-associated protein in CNS neurons. J. Neurosci. 28 14 (2008) 3604-3614
167. Skyldberg B., Fujioka K., Hellstrom A.C., Sylven L., Moberger B., and Auer G. Human papillomavirus infection, centrosome aberration, and genetic stability in cervical lesions. Mod. Pathol. 14 4 (2001) 279-284
168. Slebos R.J., Lee M.H., Plunkett B.S., Kessis T.D., Williams B.O., Jacks T., Hedrick L., Kastan M.B., and Cho K.R. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. U. S. A. 91 12 (1994) 5320-5324
169. Smith P.P., Bryant E.M., Kaur P., and McDougall J.K. Cytogenetic analysis of eight human papillomavirus immortalized human keratinocyte cell lines. Int. J. Cancer 44 6 (1989) 1124-1131
170. Smith-McCune K., Kalman D., Robbins C., Shivakumar S., Yuschenkoff L., and Bishop J.M. Intranuclear localization of human papillomavirus 16 E7 during transformation and preferential binding of E7 to the Rb family member p130. Proc. Natl. Acad. Sci. U. S. A. 96 12 (1999) 6999-7004
171. Smotkin D., and Wettstein F.O. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc. Natl. Acad. Sci. U. S. A. 83 13 (1986) 4680-4684
172. Smotkin D., and Wettstein F.O. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J. Virol. 61 (1987) 1686-1689
173. Southern S.A., Evans M.F., and Herrington C.S. Basal cell tetrasomy in low-grade cervical squamous intraepithelial lesions infected with high-risk human papillomaviruses. Cancer Res. 57 19 (1997) 4210-4213
174. Spardy N., Duensing A., Charles D., Haines N., Nakahara T., Lambert P.F., and Duensing S. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. J. Virol. 81 23 (2007) 13265-13270
175. Stanbridge E., Dez C.J., Dorsen C.-J., Nishioni R.Y., Pechl D.M., Weissman B.E., and Wilkinson J.E. Human cell hybrids: Analysis of transformation and tumorigenicity. Science 215 (1982) 252-256
176. Steinbeck R.G. Proliferation and DNA aneuploidy in mild dysplasia imply early steps of cervical carcinogenesis. Acta Oncol. 36 (1997) 3-12
177. Stoppler H., Stoppler M.C., Johnson E., Simbulan-Rosenthal C.M., Smulson M.E., Iyer S., Rosenthal D.S., and Schlegel R. The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis. Oncogene 17 10 (1998) 1207-1214
178. Storey A., Almond N., Osborn K., and Crawford L. Mutations of the human papillomavirus type 16 E7 gene that affect transformation, transactivation and phosphorylation by the E7 protein. J. Gen. Virol. 71 Pt 4 (1990) 965-970
179. Stubenrauch F., and Laimins L.A. Human papillomavirus life cycle: active and latent phases. Semin. Cancer Biol. 9 6 (1999) 379-386
180. Tanaka A., Noda T., Yajima H., Hatanaka M., and Ito Y. Identification of a transforming gene of human papillomavirus type 16. J. Virol. 63 3 (1989) 1465-1469
181. Tasaki T., Mulder L.C., Iwamatsu A., Lee M.J., Davydov I.V., Varshavsky A., Muesing M., and Kwon Y.T. A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons. Mol. Cell. Biol. 25 16 (2005) 7120-7136
182. Thomas J.T., Hubert W.G., Ruesch M.N., and Laimins L.A. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc. Natl. Acad. Sci. U. S. A. 96 15 (1999) 8449-8454
183. Tommasino M., Adamczewski J.P., Carlotti F., Barth C.F., Manetti R., Contorni M., Cavalieri F., Hunt T., and Crawford L. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 8 1 (1993) 195-202
184. Toussaint-Smith E., Donner D.B., and Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 23 17 (2004) 2988-2995
185. Trimarchi J.M., Fairchild B., Wen J., and Lees J.A. The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc. Natl. Acad. Sci. U. S. A. 98 4 (2001) 1519-1524
186. Uchida C., Miwa S., Kitagawa K., Hattori T., Isobe T., Otani S., Oda T., Sugimura H., Kamijo T., Ookawa K., Yasuda H., and Kitagawa M. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 24 1 (2005) 160-169
187. Vieira K.B.L., Goldstein D.J., and Villa L.L. Tumor necrosis factor alpha interferes with the cell cycle of normal and papillomavirus-immortalized human keratinocytes. Cancer Res. 56 (1996) 2452-2457
188. Villa L.L., Vieira K.B., Pei X.F., and Schlegel R. Differential effect of tumor necrosis factor on proliferation of primary human keratinocytes and cell lines containing human papillomavirus types 16 and 18. Mol. Carcinog. 6 1 (1992) 5-9
189. Vousden K.H., and Jat P.S. Functional similarity between HPV16E7, SV40 large T and adenovirus E1a proteins. Oncogene 4 2 (1989) 153-158
190. Vousden K.H., Doniger J., DiPaolo J.A., and Lowy D.R. The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncog. Res. 3 2 (1988) 167-175
191. Vousden K.H., Vojtesek B., Fisher C., and Lane D. HPV-16 E7 or adenovirus E1A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. Oncogene 8 6 (1993) 1697-1702
192. Warburg O. Ueber den Stoffwechsel der Tumoren (1936), Springer, Berlin
193. Watanabe S., and Yoshiike K. Transformation of rat 3Y1 cells by human papillomavirus type-18 DNA. Int. J. Cancer 41 6 (1988) 896-900
194. Watanabe S., Kanda T., Sato H., Furuno A., and Yoshiike K. Mutational analysis of human papillomavirus type 16 E7 functions. J. Virol. 64 1 (1990) 207-214
195. White E., Cipriani R., Sabbatini P., and Denton A. Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. J. Virol. 65 6 (1991) 2968-2978
196. White A.E., Livanos E.M., and Tlsty T.D. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev. 8 6 (1994) 666-677
197. Winkler B., Crum C.P., Fujii T., Ferenczy A., Boon M., Braun L., Lancaster W.D., and Richart R.M. Koilocytotic lesions of the cervix. The relationship of mitotic abnormalities to the presence of papillomavirus antigens and nuclear DNA content. Cancer 53 5 (1984) 1081-1087
198. Woodworth C.D., Bowden P.E., Doniger J., Pirisi L., Barnes W., Lancaster W.D., and DiPaolo J.A. Characterization of normal human exocervical epithelial cells immortalized in vitro by papillomavirus types 16 and 18 DNA. Cancer Res. 48 16 (1988) 4620-4628
199. Woodworth C.D., Doniger J., and DiPaolo J.A. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma. J. Virol. 63 1 (1989) 159-164
200. Woodworth C.D., Waggoner S., Barnes W., Stoler M.H., and DiPaolo J.A. Human cervical and foreskin epithelial cells immortalized by human papillomavirus DNAs exhibit dysplastic differentiation in vivo. Cancer Res. 50 (1990) 3709-3715
201. Wu E.W., Clemens K.E., Heck D.V., and Munger K. The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J. Virol. 67 4 (1993) 2402-2407
202. Xu X.Z., Wes P.D., Chen H., Li H.S., Yu M., Morgan S., Liu Y., and Montell C. Retinal targets for calmodulin include proteins implicated in synaptic transmission. J. Biol. Chem. 273 47 (1998) 31297-31307
203. Yasumoto S., Burkhardt A.L., Doniger J., and DiPaolo J.A. Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J. Virol. 57 2 (1986) 572-577
204. Yutsudo M., Okamoto Y., and Hakura A. Functional dissociation of transforming genes of human papillomavirus type 16. Virology 166 2 (1988) 594-597
205. Zatsepina O., Braspenning J., Robberson D., Hajibagheri M.A., Blight K.J., Ely S., Hibma M., Spitkovsky D., Trendelenburg M., Crawford L., and Tommasino M. The human papillomavirus type 16 E7 protein is associated with the nucleolus in mammalian and yeast cells. Oncogene 14 10 (1997) 1137-1145
206. Zerfass K., Schulze A., Spitkovsky D., Friedman V., Henglein B., and Jansen-Durr P. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J. Virol. 69 10 (1995) 6389-6399
207. Zerfass-Thome K., Zwerschke W., Mannhardt B., Tindle R., Botz J.W., and Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13 11 (1996) 2323-2330
208. Zhang Y., Xiong Y., and Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92 6 (1998) 725-734
209. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 5 (2002) 342-350
210. Zwerschke W., Mazurek S., Massimi P., Banks L., Eigenbrodt E., and Jansen-Durr P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl. Acad. Sci. U. S. A. 96 4 (1999) 1291-1296
211. Zwerschke W., Mannhardt B., Massimi P., Nauenburg S., Pim D., Nickel W., Banks L., Reuser A.J., and Jansen-Durr P. Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein. J. Biol. Chem. 275 13 (2000) 9534-9541